Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Treatment With Teclistamab and Talquetamab in Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma
NCT05849610Phase 2Active, not recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teclistamab and talquetamab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: Measurable Residual Disease negative Complete Remission rate by Next Generation Flow Cytometry at 22 months and Measurable Residual Disease negative Complete Remission rate by Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography scan at 22 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
teclistamabtalquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05849610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05849610.